Published in Proc Natl Acad Sci U S A on December 09, 2005
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol (2011) 4.18
B cell homeostasis in chronic hepatitis C virus-related mixed cryoglobulinemia is maintained through naïve B cell apoptosis. Hepatology (2012) 2.05
Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood (2007) 1.72
Hepatitis C virus-induced cryoglobulinemia. Kidney Int (2009) 1.60
Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev (2008) 1.59
Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol (2009) 1.41
HCV E2 protein binds directly to thyroid cells and induces IL-8 production: a new mechanism for HCV induced thyroid autoimmunity. J Autoimmun (2008) 1.35
Hepatitis C virus and lymphoma. J Clin Pathol (2007) 1.33
Current progress in development of hepatitis C virus vaccines. Nat Med (2013) 1.28
Hepatitis C virus proteins. World J Gastroenterol (2007) 1.28
Differential dysfunction in dendritic cell subsets during chronic HCV infection. Clin Immunol (2007) 1.17
Temporal variations in the hepatitis C virus intrahost population during chronic infection. J Virol (2011) 1.15
Chronic hepatitis C virus infection: prevalence of extrahepatic manifestations and association with cryoglobulinemia in Bulgarian patients. World J Gastroenterol (2007) 1.15
Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin. J Cell Sci (2009) 1.05
Lymphomas can develop from B cells chronically helped by idiotype-specific T cells. J Exp Med (2007) 1.05
Peripheral blood B cell subset skewing is associated with altered cell cycling and intrinsic resistance to apoptosis and reflects a state of immune activation in chronic hepatitis C virus infection. J Immunol (2010) 1.04
Persistence of viremia and production of neutralizing antibodies differentially regulated by polymorphic APOBEC3 and BAFF-R loci in friend virus-infected mice. J Virol (2010) 1.04
Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein. J Virol (2008) 1.03
Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo. Blood (2010) 1.01
Hepatitis C virus lymphotropism and peculiar immunological phenotype: effects on natural history and antiviral therapy. World J Gastroenterol (2009) 0.98
HCV and lymphoproliferation. Clin Dev Immunol (2012) 0.96
Autoimmunity and infection in Sjögren's syndrome. Curr Opin Rheumatol (2013) 0.93
Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population. Hepatology (2012) 0.93
Hepatitis C virus associated glomerulopathies. World J Gastroenterol (2014) 0.92
Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol (2008) 0.92
The role of humoral innate immunity in hepatitis C virus infection. Viruses (2012) 0.91
Antibody V(h) repertoire differences between resolving and chronically evolving hepatitis C virus infections. PLoS One (2011) 0.91
"Negative vaccination" by specific CD4 T cell tolerisation enhances virus-specific protective antibody responses. PLoS One (2007) 0.90
An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol (2013) 0.87
Immune control and failure in HCV infection--tipping the balance. J Leukoc Biol (2014) 0.87
Interferon alpha regulates MAPK and STAT1 pathways in human hepatoma cells. Virol J (2011) 0.86
Enhanced activation of memory, but not naïve, B cells in chronic hepatitis C virus-infected patients with cryoglobulinemia and advanced liver fibrosis. PLoS One (2013) 0.86
Antigenic cooperation among intrahost HCV variants organized into a complex network of cross-immunoreactivity. Proc Natl Acad Sci U S A (2015) 0.85
Pathogenetic mechanisms of hepatitis C virus-induced B-cell lymphomagenesis. Clin Dev Immunol (2012) 0.85
Immunity and hepatitis C: a review. Curr HIV/AIDS Rep (2013) 0.85
CD81 and hepatitis C virus (HCV) infection. Viruses (2014) 0.84
B-cell clonality in the liver of hepatitis C virus-infected patients. World J Gastroenterol (2009) 0.84
CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. Hum Pathol (2009) 0.83
Hepatitis C virus, cryoglobulinemia, and kidney: novel evidence. Scientifica (Cairo) (2012) 0.83
Analysis of hepatitis C virus hypervariable region 1 sequence from cryoglobulinemic patients and associated controls. J Virol (2007) 0.83
Direct effects of hepatitis C virus on the lymphoid cells. World J Gastroenterol (2013) 0.82
Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact. J Transl Med (2012) 0.82
Immunological alterations in hepatitis C virus infection. World J Gastroenterol (2013) 0.82
GBV-C infection and risk of NHL among U.S. adults. Cancer Res (2014) 0.81
Hepatitis C virus protects human B lymphocytes from Fas-mediated apoptosis via E2-CD81 engagement. PLoS One (2011) 0.81
Human herpesvirus-8 infection leads to expansion of the preimmune/natural effector B cell compartment. PLoS One (2010) 0.81
Infectious Aetiology of Marginal Zone Lymphoma and Role of Anti-Infective Therapy. Mediterr J Hematol Infect Dis (2016) 0.81
Chronic hepatitis C virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells. Clin Vaccine Immunol (2012) 0.80
Hepatitis C virus cryoglobulinemia and non-hodgkin lymphoma. Hepat Mon (2012) 0.79
Viral interactions with B-cells contribute to increased regulatory T-cells during chronic HCV infection. Viral Immunol (2011) 0.79
Virus-associated lymphomagenesis. Int J Biomed Sci (2006) 0.79
A role for CD81 and hepatitis C virus in hepatoma mobility. Viruses (2014) 0.78
Altered expression of the tetraspanin CD81 on B and T lymphocytes during HIV-1 infection. Clin Exp Immunol (2007) 0.77
Immunopathogenesis of Hepatitis C Virus Infection. Gastroenterol Clin North Am (2015) 0.77
Innate and Adaptive Immune Responses in Chronic HCV infection. Curr Drug Targets (2015) 0.77
Hepatitis C virus-related lymphomagenesis in a mouse model. ISRN Hematol (2011) 0.77
Dengue Virus Directly Stimulates Polyclonal B Cell Activation. PLoS One (2015) 0.76
Pathophysiological Relationship between Infections and Systemic Vasculitis. Autoimmune Dis (2015) 0.76
Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options. World J Hepatol (2016) 0.76
Preferential association of hepatitis C virus with CD19(+) B cells is mediated by complement system. Hepatology (2016) 0.76
EBV, HCMV, HHV6, and HHV7 screening in bone marrow samples from children with acute lymphoblastic leukemia. Biomed Res Int (2014) 0.75
Vasculitic syndromes in hepatitis C virus: A review. J Adv Res (2016) 0.75
Hepatitis C virus and non-Hodgkin's lymphomas: A minireview. J Adv Res (2016) 0.75
Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know? Ther Adv Hematol (2015) 0.75
Hepatitis C virus has a genetically determined lymphotropism through co-receptor B7.2. Nat Commun (2017) 0.75
Hepatitis C virus infection and thyroid autoimmune disorders: A model of interactions between the host and the environment. World J Hepatol (2016) 0.75
CD100 up-regulation induced by interferon-α on B cells is related to hepatitis C virus infection. PLoS One (2014) 0.75
Pre-stimulation of CD81 expression by resting B cells increases proliferation following EBV infection, but the overexpression of CD81 induces the apoptosis of EBV-transformed B cells. Int J Mol Med (2015) 0.75
Hepatitis C virus and neurological damage. World J Hepatol (2016) 0.75
Progress in the development of vaccines for hepatitis C virus infection. World J Gastroenterol (2015) 0.75
Abnormal phenotypic features of IgM+B cell subsets in patients with chronic hepatitis C virus infection. Exp Ther Med (2017) 0.75
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Binding of hepatitis C virus to CD81. Science (1998) 12.40
Determination of lymphocyte division by flow cytometry. J Immunol Methods (1994) 11.48
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A (2001) 11.06
Maintenance of serological memory by polyclonal activation of human memory B cells. Science (2002) 8.75
A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med (1992) 8.06
CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol (1998) 4.01
Hepatitis C: the clinical spectrum of disease. Hepatology (1997) 3.94
A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A (1996) 3.25
CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci U S A (2004) 3.01
CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science (1992) 2.79
Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med (2002) 2.64
The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu Rev Immunol (1995) 2.64
Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol (1999) 2.61
Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J Virol (1993) 2.58
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood (2005) 2.50
The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol (1992) 2.17
Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol (2003) 2.13
Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med (1993) 1.90
High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology (1995) 1.88
Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur J Immunol (2001) 1.67
Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood (2003) 1.62
Transmembrane-4 superfamily proteins CD81 (TAPA-1), CD82, CD63, and CD53 specifically associated with integrin alpha 4 beta 1 (CD49d/CD29). J Immunol (1996) 1.54
Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. Hepatology (2004) 1.50
Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes. J Exp Med (1993) 1.44
Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells. J Virol (2005) 1.40
Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi-center case-control study. Int J Cancer (2004) 1.32
Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients. J Immunol (2003) 1.19
Functional B-cell response in intrahepatic lymphoid follicles in chronic hepatitis C. Hepatology (1999) 1.16
The TAPA-1 molecule is associated on the surface of B cells with HLA-DR molecules. J Immunol (1993) 1.14
Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med (2003) 4.20
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology (2012) 3.12
Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med (2002) 2.64
Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine (2011) 2.53
Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A (2009) 2.41
How Drosophila combats microbial infection: a model to study innate immunity and host-pathogen interactions. Curr Opin Microbiol (2002) 2.39
Prospects for a vaccine against the hepatitis C virus. Nature (2005) 2.38
Vaccines for the twenty-first century society. Nat Rev Immunol (2011) 2.34
SARS--beginning to understand a new virus. Nat Rev Microbiol (2003) 2.30
PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest (2009) 2.26
Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest (2004) 2.25
The way forward in HCV treatment--finding the right path. Nat Rev Drug Discov (2007) 2.24
Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A (2007) 2.20
Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol (2005) 2.20
An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes. Blood (2009) 2.13
Distinct microRNA signatures in human lymphocyte subsets and enforcement of the naive state in CD4+ T cells by the microRNA miR-125b. Nat Immunol (2011) 2.11
Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. J Hepatol (2010) 2.03
CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med (2003) 2.01
New adjuvants for human vaccines. Curr Opin Immunol (2010) 1.98
Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun (2002) 1.94
Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection. Nat Med (2007) 1.82
Neutrophils efficiently cross-prime naive T cells in vivo. Blood (2007) 1.67
Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood (2007) 1.67
Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus-infected liver tissue. Hepatology (2014) 1.58
Phylogeny of the SARS coronavirus. Science (2003) 1.56
Association of hepatitis C virus envelope proteins with exosomes. Eur J Immunol (2004) 1.51
Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. J Exp Med (2005) 1.50
Long-term results of drug-eluting balloon angioplasty for treatment of refractory recurrent carotid in-stent restenosis. J Endovasc Ther (2014) 1.47
Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A (2011) 1.44
Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood (2013) 1.42
The path to a successful vaccine adjuvant--'the long and winding road'. Drug Discov Today (2009) 1.41
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology (2011) 1.40
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood (2013) 1.39
IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur J Immunol (2006) 1.36
miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Hum Immunol (2009) 1.34
Mechanism of action of licensed vaccine adjuvants. Vaccine (2009) 1.34
Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis (2010) 1.30
Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells (2008) 1.28
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine (2010) 1.28
NKT-cell help to B lymphocytes can occur independently of cognate interaction. Blood (2008) 1.28
Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine (2007) 1.28
Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J Virol (2004) 1.27
Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol (2005) 1.27
MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines (2011) 1.25
Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. J Virol (2003) 1.25
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine (2007) 1.24
Immunology of TLR-independent vaccine adjuvants. Curr Opin Immunol (2009) 1.24
Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J Biol Chem (2004) 1.24
Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity. PLoS Pathog (2012) 1.23
Follicular helper NKT cells induce limited B cell responses and germinal center formation in the absence of CD4(+) T cell help. J Immunol (2012) 1.22
Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells. Virology (2005) 1.22
Evaluating the efficiency of isotope transmission for improved panel design and a comparison of the detection sensitivities of mass cytometer instruments. Cytometry A (2015) 1.21
A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One (2013) 1.16
Early therapy in HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response. Antivir Ther (2008) 1.13
Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol (2004) 1.12
Activation of src-family tyrosine kinases by LPS regulates cytokine production in dendritic cells by controlling AP-1 formation. Eur J Immunol (2003) 1.12
Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis (2011) 1.10
MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action. J Immunol (2012) 1.10
Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Hum Vaccin (2009) 1.10
Role of microRNAs and long-non-coding RNAs in CD4(+) T-cell differentiation. Immunol Rev (2013) 1.09
IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood (2011) 1.07
Variable patterns of programmed death-1 expression on fully functional memory T cells after spontaneous resolution of hepatitis C virus infection. J Virol (2008) 1.03
CCR6 is expressed on an IL-10-producing, autoreactive memory T cell population with context-dependent regulatory function. J Exp Med (2010) 1.03
Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection: exploring the immunological mechanisms. Eur J Immunol (2004) 1.02
Differential IL-17 production and mannan recognition contribute to fungal pathogenicity and commensalism. J Immunol (2010) 1.02
A novel animal model to study non-spontaneous bisphosphonates osteonecrosis of jaw. J Oral Pathol Med (2010) 0.99
Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. Virology (2002) 0.99
T cell costimulation by the hepatitis C virus envelope protein E2 binding to CD81 is mediated by Lck. Eur J Immunol (2003) 0.99
Normalization of circulating microRNA expression data obtained by quantitative real-time RT-PCR. Brief Bioinform (2015) 0.98
Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo. Clin Vaccine Immunol (2008) 0.97
Long-lasting memory-resting and memory-effector CD4+ T cells in human X-linked agammaglobulinemia. Blood (2002) 0.97
The Second Canadian Symposium on hepatitis C virus: a call to action. Can J Gastroenterol (2013) 0.96
Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie (2008) 0.96
Minimum data elements for research reports on CFS. Brain Behav Immun (2012) 0.96
Cyclic AMP modulates the functional plasticity of immature dendritic cells by inhibiting Src-like kinases through protein kinase A-mediated signaling. J Biol Chem (2004) 0.96